Abstract

Hypothyroidism exacerbating valproate induced hyperammonemic delirium, an unknown clinical concern: Short communication

Author(s): Chung-Chieh Hung

From the literature reviews, valproic acid (VPA) induced hyperammonemia is a commonly adverse event and usually asymptomatic. VPA is a well-tolerated and an effective agent for the treatment of epilepsy, bipolar disorder, schizoaffective disorder, off-lable use for the impulsive control problems and etc. However, several case reports have indicated that VPA may induce serious symptomatic hyperammonemia and even lethal. Based on the analysis of susceptible patients, several possible mechanisms and risk factors have been proposed to identify the patients at risk.